@ARTICLE{
author={Jelicic Jelena J,Juul-Jensen Karen,Bukumiric Zoran M,Simonsen Mikkel Runason,Clausen Michael Roost,Al-Mashhadi Ahmed Ludvigsen,Pedersen Robert Schou,Poulsen Christian Bjorn,Gang Anne Ortved,Brown Peter,El-Galaly Tarec Christoffer,Larsen Thomas Stauffer},
year={2026},
title={International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma},
journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA},
volume={26},
number={1},
pages={e62-e76},
document_type={Article},
} 

@ARTICLE{
author={Jelicic Jelena J,Juul-Jensen Karen,Bukumiric Zoran M,Jorgensen Rasmus Rask Kragh,Simonsen Mikkel Runason,Clausen Michael Roost,Al-Mashhadi Ahmed,Pedersen Robert,Poulsen Christian,Gang Anne Ortved,Brown Peter,El-Galaly Tarec Christoffer,Larsen Thomas Stauffer},
year={2025},
title={Challenges in comparing outcomes of frontline clinical trials for diffuse large B-cell lymphoma patients selected based on the international index: A real-world from the danish lymphoma registry},
journal={BLOOD},
volume={146},
number={},
pages={896-897},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Jelicic Jelena J,Juul Jensen Karen,Bukumiric Zoran M,Simonsen Mikkel Runason,Clausen Michael Roost,Al Mashhadi Ahmed Ludvigsen,Pedersen Robert Schou,Poulsen Christian Bjorn,Gang Anne Ortved,Brown Peter,El Galaly Tarec Christoffer Christoffer,Larsen Thomas Stauffer},
year={2024},
title={Identifying Trial-Eligible High- and High-Intermediate Risk Patients with Diffuse Large B-Cell Lymphoma Using Prognostic Models: A Real-Life Comparative Analysis of IPI, aaIPI and NCCN-IPI from Danish Study Group},
journal={BLOOD},
volume={144},
number={},
pages={650-651},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Jelicic Jelena J,Juul Jensen Karen,Bukumiric Zoran M,Simonsen Mikkel Runason,Clausen Michael Roost,Al Mashhadi Ahmed Ludvigsen,Pedersen Robert Schou,Poulsen Christian Bjorn,Gang Anne Ortved,Brown Peter,El Galaly Tarec Christoffer,Larsen Thomas Stauffer},
year={2024},
title={Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma},
journal={CANCER MEDICINE},
volume={13},
number={12},
pages={-},
document_type={Article},
}